Cinacalcet may reduce arterial stiffness in patients with chronic renal disease and secondary hyperparathyroidism - Results of a small-scale, prospective, observational study

Clinical Nephrology

Volumn 75, Issue 3, 2011, Pages 181-187

  Bonet, J ^a   Bayes B ^a,b   Fernandez Crespo P ^a   Casals, M ^a   Lopez Ayerbe J ^a   Romero, R ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Arterial stiffness; Cardiovascular risk; Cinacalcet; Pulse wave velocity; Vascular calcification

Indexed keywords

ALKALINE PHOSPHATASE; CINACALCET; PARATHYROID HORMONE;

ADULT; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; DIALYSIS; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; MALE; OBSERVATIONAL STUDY; PHOSPHATE BLOOD LEVEL; PULSE WAVE; SECONDARY HYPERPARATHYROIDISM;

ADULT; AGED; ALKALINE PHOSPHATASE; AORTA; AORTIC DISEASES; BIOLOGICAL MARKERS; BLOOD PRESSURE; CALCIMIMETIC AGENTS; CALCIUM; ELASTICITY; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; PROSPECTIVE STUDIES; PULSATILE FLOW; RENAL DIALYSIS; SPAIN; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 79951918150     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP75181     Document Type: Article

References (27)

1. Hodis S, Zamir M. Mechanical events within the arterial wall: The dynamic context for elastin fatigue. J Biomech. 2009; 42: 1010-1016.
2. Verbeke F, Van Biesen W, Peeters P, Van Bortel LM, Vanholder RC. Arterial stiffness and wave reflections in renal transplant recipients. Nephrol Dial Transplant. 2007; 22: 3021-3027. (Pubitemid 350093449)
3. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999; 99: 2434-2439. (Pubitemid 29218240)
4. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation. 2002; 106: 2085-2090.
5. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001; 37: 1236-1241. (Pubitemid 34163575)
6. Meaume S, Benetos A, Henry OF, Rudnichi A, Safar ME. Aortic pulse wave velocity predicts cardiovascular mortality in subjects > 70 years of age. Arterioscler Thromb Vasc Biol. 2001; 21: 2046-2050. (Pubitemid 34219760)
7. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006; 27: 2588-2605. (Pubitemid 44627304)
8. Cozzolino M, Pasho S, Fallabrino G, Olivi L, Gallieni M, Brancaccio D. Pathogenesis of secondary hyperparathyroidism. Int J Artif Organs. 2009; 32: 75-80.
9. de Francisco AL, Pinera C, Palomar R, Arias M. Impact of treatment with calcimimetics on hyperparathyroidism and vascular mineralization. J Am Soc Nephrol. 2006; 17 (Suppl): 281-285.
10. McCullough PA, Soman S. Cardiovascular calcification in patients with chronic renal failure: are we on target with this risk factor? Kidney Int. 2004; 90 (Suppl): 18-24.
11. Quarles LD. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease. Kidney Int. 2005; 96 (Suppl): 24-28.
12. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004; 350: 1516-1525. (Pubitemid 38477776)
13. Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D et al. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar(R)/Mimpara(R)) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant. 2005; 20: 1370-1377.
14. Block GA. The impact of calcimimetics on mineral metabolism and secondary hyperparathyroidism in end-stage renal disease. Kidney Int. 2003; 87 (Suppl): 131-136.
15. Garred LJ, Barichello DL, DiGiuseppe B, McCready WG, Canaud BC. Simple Kt/V formulas based on urea mass balance theory. Asaio J. 1994; 40: 997-1004. (Pubitemid 24372229)
16. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension. 1995; 26: 485-490.
17. Wojciechowska W, Staessen JA, Nawrot T, Cwynar M, Seidlerova J, Stolarz K et al. Reference values in white Europeans for the arterial pulse wave recorded by means of the SphygmoCor device. Hypertens Res. 2006; 29: 475-483. (Pubitemid 44363463)
18. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W et al. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol. 2002; 13: 1017-1024. (Pubitemid 34274098)
19. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003; 63: 248-254. (Pubitemid 35463928)
20. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 2003; 14: 575-583. (Pubitemid 36246000)
21. KDIGO. Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2009; 113 (Suppl): 1-130.
22. Blayney MJ, Pisoni RL, Bragg-Gresham JL, Bommer J, Piera L, Saito A et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int. 2008; 74: 655-663.
23. Regidor DL, Kovesdy CP, Mehrotra R, Rambod M, Jing J, McAllister CJ et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol. 2008; 19: 2193-2203.
24. Garside R, Pitt M, Anderson R, Mealing S, Roome C, Snaith A et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess. 2007; 11: 1-167.
25. Blacher J, Asmar R, Djane S, London GM, Safar ME. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension. 1999; 33: 1111-1117. (Pubitemid 29230958)
26. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001; 103: 987-992. (Pubitemid 32183805)
27. Lopez I, Aguilera-Tejero E, Mendoza FJ, Almaden Y, Perez J, Martin D et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol. 2006; 17: 795-804.